Role of Octreotide in Conservative Management of Chyle Leak Post Neck Dissection in Cases of Head Neck Cancer: A Retrospective Analysis.
Chyle leak
Head neck cancers
Neck dissection
Octreotide
Journal
Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
ISSN: 2231-3796
Titre abrégé: Indian J Otolaryngol Head Neck Surg
Pays: India
ID NLM: 9422551
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
24
02
2021
accepted:
27
06
2021
entrez:
6
2
2023
pubmed:
7
2
2023
medline:
7
2
2023
Statut:
ppublish
Résumé
Chyle leak is a dreadful complication in patients undergoing neck dissections. Octreotide has been used in the management of chyle leak post neck dissections in head and neck cancer patients. Currently there is no consensus and practice guidelines on the same. (1) To study the role of octreotide in early cessation of post neck dissection chyle leak. (2) To study incidence of intra-operative and post-operative CL, its relation to the extent of nodal disease and neck dissection, prior radiotherapy. Retrospective analysis of 16 patients out of 529 neck dissection over a period of 03 years between Jan 2016 and Dec 2019 who developed post-operative chyle leak. All patients who had post-operative chyle leak were administered octreotide. Time taken for chyle leak to stop was primary outcome. Secondary outcomes were duration of hospitalization post-operatively, incidence of intra-operative and post-operative chyle leak, its relation to the extent of nodal disease, prior radiotherapy and type of neck dissection. 59 of 529 neck dissections (11.15%) were noted to have intra-operative chyle leak. 16 of 529 neck dissections (3.02%) developed post-operative chyle leak. On applying chi square test, prior multimodality and N plus neck were found to be significant risk factors in developing postoperative chyle leak. Considering only RT versus no RT in prior multimodality treated group, the difference was insignificant. Onset of chyle leak varied from 1 to 5 post-op day (mean 2.68 days). 15 (93.75%) patients responded to octreotide. Chyle leak resolved between 3 and 10 days (mean 5.18 days) and octreotide was given for 5-12 days (mean-7.18 days). Overall duration of hospitalization ranged from 09 to 18 days (mean 12.18 days). 01 patient (6.25%) had to be re-explored due to high volume leak despite using octreotide. Adverse effects of octreotide were minimal and tolerable. Octreotide is effective in reducing the duration of chyle leak, hospital stay and need for surgical intervention. It may be considered as suitable adjunct to conservative measures in the management for post-operative chyle leak.
Identifiants
pubmed: 36742480
doi: 10.1007/s12070-021-02746-y
pii: 2746
pmc: PMC9895617
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6078-6086Informations de copyright
© Association of Otolaryngologists of India 2021.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interests.
Références
Diabetes. 1981 May;30(5):440-5
pubmed: 6112179
J Surg Oncol. 2007 Aug 1;96(2):176-7
pubmed: 17372924
J Anat. 1973 May;115(Pt 1):45-52
pubmed: 4728265
Laryngoscope. 2012 May;122(5):997-9
pubmed: 22447207
J Korean Med Sci. 2010 Apr;25(4):541-5
pubmed: 20357995
J Plast Reconstr Aesthet Surg. 2011 Sep;64(9):e223-30
pubmed: 21296632
Am J Otolaryngol. 2010 Sep-Oct;31(5):395-6
pubmed: 20015785
N Engl J Med. 2015 Aug 6;373(6):521-9
pubmed: 26027881
ORL J Otorhinolaryngol Relat Spec. 2004;66(3):148-54
pubmed: 15316236
J Otolaryngol. 1987 Jun;16(3):174-8
pubmed: 3599173
Plast Reconstr Surg. 2011 Jan;127 Suppl 1:105S-115S
pubmed: 21200280
Ann Thorac Surg. 1998 Jul;66(1):253-4
pubmed: 9692478
Curr Opin Otolaryngol Head Neck Surg. 2013 Apr;21(2):150-6
pubmed: 23449286
Asian Cardiovasc Thorac Ann. 2005 Sep;13(3):222-4
pubmed: 16112992
Clin Anat. 2014 May;27(4):637-44
pubmed: 24302465
Clin Exp Otorhinolaryngol. 2016 Jun;9(2):173-7
pubmed: 27090270
J Otolaryngol Head Neck Surg. 2016 Oct 18;45(1):52
pubmed: 27756377
Am J Otolaryngol. 1998 Jul-Aug;19(4):257-62
pubmed: 9692635
Head Neck. 1996 Jul-Aug;18(4):347-51
pubmed: 8780946
Otolaryngol Head Neck Surg. 2003 Jun;128(6):910-1
pubmed: 12825049
Br J Oral Maxillofac Surg. 2009 Sep;47(6):478-80
pubmed: 19493595
Neurosurgery. 2003 Dec;53(6):1385-7; discussion 1387-8
pubmed: 14633304
Laryngoscope. 2015 Jul;125(7):1624-7
pubmed: 25639346
JAMA Otolaryngol Head Neck Surg. 2015 Aug;141(8):723-7
pubmed: 26135979
Otolaryngol Head Neck Surg. 2000 Jan;122(1):31-8
pubmed: 10629479
Head Neck. 2012 Nov;34(11):1570-3
pubmed: 22290583
Am J Otolaryngol. 1992 Sep-Oct;13(5):306-9
pubmed: 1285563
Head Neck. 2018 Jan;40(1):7-15
pubmed: 29120521
Laryngoscope. 1976 Jun;86(6):804-13
pubmed: 933672
Curr Opin Pulm Med. 2006 Jul;12(4):264-7
pubmed: 16825878
Int J Otolaryngol. 2017;2017:8362874
pubmed: 28203252
Br J Oral Maxillofac Surg. 2012 Apr;50(3):197-201
pubmed: 21376436
Ear Nose Throat J. 2017 Jul;96(7):264-267
pubmed: 28719710
Eur J Cancer Care (Engl). 2010 Jul;19(4):510-5
pubmed: 20030699
Otolaryngol Clin North Am. 2008 Dec;41(6):1231-40, xi
pubmed: 19040982
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1000-6
pubmed: 26286200
Ann Vasc Surg. 2007 Jan;21(1):90-2
pubmed: 17349344
Ann Surg Oncol. 2008 Feb;15(2):424-9
pubmed: 17999116
Otolaryngol Head Neck Surg. 2000 Mar;122(3):434-9
pubmed: 10699823